Solid Tumor Research Grant Scientific Focus (ACE)

Solid Tumor Research Grant Scientific Focus (ACE) is sponsored by Gilead Sciences, Inc.. This program supports research in solid tumors, including endometrial cancer.

Solid Tumor Research Grant Scientific Focus (ACE) | Gilead : Research Scholars The program is designed to support pre-clinical and clinical research in the field of Oncology Solid Tumors in Australia, Canada, and Europe. For the 2026 cycle, the program will focus on breast, endometrial, and lung cancer .

Areas of research may include, but are not limited to: Disparities and inequities in cancer care Agnostic approaches to target solid tumors Combinational drug strategies/approaches to treatment Resistance mechanism identification/novel approaches to addressing resistance mechanisms Transformative, therapeutic modalities/approaches to treatment Patient-specific factors that are predictors of toxicity Genomic polymorphisms and impact treatment response Novel targets and/or biomarkers/imaging techniques Novel diagnostic, prevention, and treatment strategies Research to improve Quality of Life (QoL) Patient-Reported Outcomes (PRO's) e.

g adverse events, addressing unmet needs for patients Any other pre-clinical or clinical research that addresses an unmet medical need or gap in scientific knowledge Gilead Affiliated Products Proposals investigating Gilead product(s) are not eligible for funding through the Research Scholars Program.

Proposals involving Gilead product(s) should be submitted for review under the Externally-Sponsored Research Grant Program through the ESR online portal . Awards granted under the program may not be duplicative of funding from institutional or hospital, other governmental, non-governmental, or industry sources.

Applicants seeking an award for research projects that are currently receiving or may receive partial funding from other sources are required to submit appropriate evidence, including budget information related to the other sources, to demonstrate that there is no direct overlap in funding.

Gilead Internal Validation The Research Scholars Program is intended to support independent research by emerging investigators that is unrelated to Gilead’s strategies or priorities.

However, all research projects selected by the Scientific Review Committee will need to be approved by an internal validation committee that, in rare circumstances, may be unable to support certain clinical interventional studies (e.g., studies focused solely on the safety and/or efficacy of non-Gilead products).

Proposals are reviewed by an independent Scientific Review Committee, (no Commercial involvement in review or selection, i.e., Marketing, Sales, and Commercial Strategy), and are reviewed based upon the criteria outlined on this website. View Application Essentials to discover specific application details. Is the RSP award funded by the Gilead Foundation or the "For-Profit Company"?

The award is an industry sponsored award funded by Gilead Sciences, Inc. which is a for profit entity, not the Gilead Foundation. While the award is funded by Gilead Sciences, Inc., the review of the applications and selection of awardees is carried out by an independent scientific review committee. Gilead is not part of the scientific review committee and has no involvement in selecting the applications that receive the awards.

Does the stated approximate protected time need to be specific to this award, or can it be for research in general? The approximate protected time refers to time spent on research in general. This time does not need to be spent only on research related to your RSP proposal.

Can I share the focus of my proposal to ensure the subject is something that would be appealing to the RSP committee for funding? The RSP Coordinator can’t provide feedback on proposed studies. Please carefully review the Scientific Focus page to ensure your proposal is in line with the program focus.

Scientific Review Committee